Department of Health, Human Performance and Recreation/Office for Sport Concussion Research, University of Arkansas, Fayetteville.
Department of Psychology, Saint Joseph's University, Philadelphia, PA.
J Athl Train. 2024 Sep 1;59(9):934-940. doi: 10.4085/1062-6050-0325.23.
The Concussion Clinical Profiles Screening Tool (CP Screen) self-report concussion symptom inventory is often administered at weekly intervals. However, 1-week reliable change indices (RCIs) for clinical cutoffs and the test-retest reliability of the CP Screen are unknown.
To document RCI cutoff scores and 1-week test-retest reliability for each profile and modifier of the CP Screen for men and women.
Case series.
A large US university.
One hundred seventy-three healthy college students.
MAIN OUTCOME MEASURE(S): Participants completed 2 administrations of the CP Screen 7 days apart. The CP Screen items yielded 5 clinical profiles and 2 modifiers. Spearman ρ coefficients (rs), intraclass correlation coefficients (ICCs), single measures, and unbiased estimates of reliability (UERs) were used to assess test-retest reliability. Wilcoxon signed-rank tests assessed differences across time. Reliable change index values and cutoff scores are provided at 90%/95% CIs. All analyses were performed for the total sample and separately for men and women.
Reliable change index cutoffs for clinically significant change (increase/decrease) at a 90% CI for men were as follows: ocular, vestibular >2/>4; anxiety/mood, cognitive/fatigue, and migraine >3/>3; sleep >4/>6; and neck >2/>2. Reliable change index cutoffs for clinically significant change (increase/decrease) at a 90% CI for women were as follows: anxiety/mood ≥2/≥4; cognitive/fatigue, migraine, ocular, vestibular, and sleep ≥3/≥3; and neck ≥1/≥1. Correlations for the CP Screen ranged from 0.51 (migraine) to 0.79 (anxiety/mood) for the total sample, from 0.48 (migraine) to 0.84 (vestibular) for men, and from 0.51 (migraine) to 0.77 (ocular) for women. Test-retest indices for each profile and modifier were moderate to good for the total sample (ICC, 0.64-0.82; UER, 0.79-0.90), men (ICC, 0.60-0.87; UER, 0.76-0.94), and women (ICC, 0.64-0.80; UER, 0.78-0.89).
The CP Screen is reliable and stable across a 1-week interval, and established RCIs for men and women can help identify meaningful change throughout recovery.
脑震荡临床特征筛查工具(CP Screen)的自我报告脑震荡症状清单通常以每周一次的间隔进行。然而,目前尚不清楚用于临床临界值的 1 周可靠变化指数(RCI)以及 CP Screen 的测试-再测试信度。
记录 CP Screen 中每个特征和修饰符的男性和女性的 RCI 临界值分数和 1 周的测试-再测试信度。
病例系列。
美国一所大型大学。
173 名健康大学生。
参与者在相隔 7 天的时间内完成了 2 次 CP Screen 测试。CP Screen 的项目产生了 5 个临床特征和 2 个修饰符。采用斯皮尔曼 ρ系数(rs)、组内相关系数(ICC)、单测和可靠性的无偏估计值(UER)来评估测试-再测试的可靠性。Wilcoxon 符号秩检验评估了时间上的差异。在 90%/95%CI 下提供可靠变化指数值和临界值分数。所有分析均针对总样本进行,并分别针对男性和女性进行。
男性 90%CI 时用于临床显著变化(增加/减少)的可靠变化指数临界值如下:眼震,前庭 >2/>4;焦虑/情绪,认知/疲劳和偏头痛 >3/>3;睡眠 >4/>6;颈部 >2/>2。女性 90%CI 时用于临床显著变化(增加/减少)的可靠变化指数临界值如下:焦虑/情绪≥2/≥4;认知/疲劳,偏头痛,眼震,前庭和睡眠≥3/≥3;颈部≥1/≥1。CP Screen 的相关性范围从总样本的 0.51(偏头痛)到 0.79(焦虑/情绪),男性为 0.48(偏头痛)到 0.84(前庭),女性为 0.51(偏头痛)到 0.77(眼震)。对于总样本,每个特征和修饰符的测试-再测试指标为中等至良好(ICC,0.64-0.82;UER,0.79-0.90),男性为(ICC,0.60-0.87;UER,0.76-0.94),女性为(ICC,0.64-0.80;UER,0.78-0.89)。
CP Screen 在 1 周的时间内是可靠且稳定的,为男性和女性建立的可靠变化指数(RCI)可以帮助识别整个恢复期的有意义变化。